VivoSeq
Oncology

Malignancy

0

Pipeline Programs↗

5

Active Trials↗

4

Companies Involved↗

Malignancy is an early-stage landscape with 0 programs across 4 companies. The most active players are Johnson & Johnson, Amgen, GSK.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

73/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Johnson & Johnson logo

Johnson & Johnson

0 programs

PreclinicalAmgen logo

Amgen

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalA

Alethia Biotherapeutics

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

19

clinical trials

Completed8 · 42%
Unknown status3 · 16%
Withdrawn2 · 11%
Active, not recruiting2 · 11%
Recruiting2 · 11%
Not yet recruiting1 · 5%
Other1 · 5%

Clinical Trials

Trial Activity

19 trials

Phase II Trial of Maribavir for CMV in Patients With Lymphoid Malignancy on Bispecific Antibodies
Recruiting·SSeoul National University Hospital·Phase 2·NCT07014319·20 enrolled
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
Recruiting·Alliance for Clinical Trials in Oncology·N/A·NCT04242095·240 enrolled
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
Active, not recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT03674411·22 enrolled
Epidemiology of Complications After Solid Organ Transplantation - EpCOT Study
Active, not recruiting·UUniversity of Birmingham·N/A·NCT02991105·85,410 enrolled
PET Imaging of 68Ga-NOTA-H006 in Malignancy
Not yet recruiting·—·N/A·NCT06162988·15 enrolled
A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT03301207·25 enrolled
HPPH and PDT for Pleural Malignancy
Completed·—·Phase 1·NCT01673074·37 enrolled
AMG 319 Lymphoid Malignancy FIH
Completed·Amgen logoAmgen·Phase 1·NCT01300026·28 enrolled
Study of GemOx and Vandetanib in Advanced Solid Malignancy
Completed·—·Phase 1·NCT00660725·22 enrolled
Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT05065866·14 enrolled
Malignancy Meta Analysis for BRL49653
Completed·GSK logoGSK·N/A·NCT01195259·1 enrolled
Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy
Completed·AAlethia Biotherapeutics·Phase 1·NCT02412462·15 enrolled
Lineberger Comprehensive Cancer Center (LCCC) 1937: Immuno-Oncology Database and Bioregistry: Identifying Mechanisms of Autoimmune Diseases in the Era of Cancer Immunotherapy.
Completed·UUNC Lineberger Comprehensive Cancer Center·N/A·NCT04656873·32 enrolled
Study of Arixtra (Fondaparinux Sodium) to Prevent Blood Clots in Women Undergoing Abdominopelvic Surgery for Likely Gynecologic Malignancy
Terminated·UUniversity of Alabama at Birmingham·Phase 3·NCT00539942·7 enrolled
Photodynamic Therapy During Surgery in Treating Patients With Pleural Malignancy
Withdrawn·OOhio State University Comprehensive Cancer Center·N/A·NCT02106559
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)